HPV and condom labeling
This article was originally published in The Gray Sheet
Executive Summary
House Government Reform/Human Resources Subcommittee hearing Jan. 28 on human papillomavirus and the "best strategies" to prevent HPV infection postponed until Feb. 5 (1"The Gray Sheet" Jan.12, 2004, p. 17). The National Cancer Institute had been asked to testify on HPV and cervical cancer vaccine research, diagnostic technologies, treatment options, consequences and prevention strategies by Subcommittee Chair Mark Souder (R-Ind.). Also asked to testify were the heads of CDC, FDA and CMS...
You may also be interested in...
HPV Diagnostics, Condom Labeling Will Be Focus Of Jan. 28 House Hearing
FDA and the National Cancer Institute are among federal agencies asked to testify on cervical cancer prevention and research at a Jan. 28 hearing of the House Government Reform/Human Resources Subcommittee
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.